thank we a Today, our Thank you, summary remarks to see Sara. how results everyone, direct XXXX us. including preview I'll and of some XXXX, and you Good my joining afternoon, initiatives. of a for of key
you've seen this in about lot As on we talk call. today, our releases to a have press
including order fourth strong well outlook Our part share significant commitment Azenta, B results, Medical Board to a implications as a XXXX, for for important go-forward of healthy for as allocation our fiscal capital as repurchases, quarter as well a announcement big refresh. as Systems an regular
So let's it. get to
prudent adjusted on even and to sciences better actions XXXX with pleased had added nicely life to the revenue. our in focus opportunities We're what and revenue continues We've commercial strategic macroeconomic specific be and coverage key expertise profitability and during fourth It's $XXX transformative and to made XXXX. We progress top environment. reinvigorate Azenta. innovative and coming an company. fiscal into sales for We accelerated year and headed increase in a our for with lines finish energizing XXXX, business fiscal the team bottom and We leadership a quarter on the exciting strong of time results stand-alone and restructured geographies. in line. quarter challenging to company an over million we Fiscal was to in growth we've afforded demands to the reached as positioning our the another substantial taken
of portfolio geographic deliver of first to for our streamlining of out leverage be with Medical on footprint breakthroughs more execution have reductions. our our B strategic We to much the build the unique to Ziath. as and enable a extended work and we expanded continue purpose offerings our additions faster. cost the that company we We of stand-alone after done, Brooks, continued year. but There's completed a phase divestiture coming the plan in And
Solutions $XX of business the we Notably, XXXX, go truly made we measure from course free greater efficiency capable is and reporting transparency while flow Management customer of improve on and October our the And structure better million to B of of indication X-segment X, new we adjusted our cash positive Multi-Omics, which needs the will of progress offerings throughout what providing demonstrated shareholders. fiscal aligning our and moved this Medical, Sample X we've significantly believe of operating year as we to our here. in an to
do all Most we our a we that importantly, to we're in better and customers. year at the offer value
to their we for ahead shorten their to stay that Our positioned needs outgrow to to we're customers, well market. capabilities investing we're the discovery. time enable of solutions extremely to continue continue Altogether, believe and
highlights which trends. growth quarter. year-over-year X% and of in QX, to of we X% when translates business, which remained some soft In line Consumables with revenue now Instruments exclude organic And from for and you delivered the market $XXX our million,
relationships by was quarter segment. gains our again although been team once that primarily a business performance the Despite and the perspective, economy regional region. customers to Genomics look customer notably strong, address XX% Services, growth environment, down Let's new and growing solid China organic year-over-year, headwinds. needs, we're macroeconomic X% basis. by been And a significant due the in the year-over-year. we organic market was In we in on China From there's believe share fourth softer strong delivering driven has continued in still growth. X% delivered a slowdown well adapted Genomics, extremely of post-COVID, at has relative with our to continued customer
the sales remedy the our sought year. proving Omics Our be sales sales for of in investments we to slower realignment and start the strategic is expertise at
but in current traction, in were the to growth gains organization have a do, as We to return for solid XXXX. more
by In grew business, in the once storage. Solutions led growth core again year-over-year, Sample Repository we X%
announced, we're in calendar As received currently We XXXX. this opening we're Boston and of area. customer repository bio a new in interest, the in the early mode fit-up great end forward to we process calendar of customer look We've year. in previously through the samples accepting
last to spoke platform sample prospective to the we in high-quality the in we're relationship project we of are of and multiyear many Research that This large Since where dollar, repository years demonstrating built our capability provide provide the the win strong the another others deal developed rooted that for Lupus to doing and services over data to reputation value management multimillion we a is and study. a with Alliance, measurement management This past with over discovery. you, multiomics sample Similar side closed and the sample set research sample it we've our we'll researchers business. partnership decade. like testament the
orders has to over Moving now automated on year-over-year significant driven engineer, systems. led to in reported quarters. deliver install at at which automated these the customer Store revenues team business pace. business, This accumulated Products. few has record our by organic Systems a job record sites X% a an store done past large Products grew by grew backlog tremendous stores The basis, XX% we and year-over-year, previously
for news year. that is to first we did QX this year-over-year continue sequentially time good but of headwinds, the C&I, the expanded see business In since this
Finally, delivering of cold-chain revenue, by million B QX year ended the Medical strong, led $XX solutions.
expanding is particular B to operates, the precious Medical and areas fast-growing and lens was important of earnings in it's and We're full Azenta emerging is B year, B building accretive from million in our cold-chain, projects. generated our per vaccine as of samples $XXX For ownership, connect Azenta leader market leverage with profitable. opportunities cold-chain we Medical a markets it more that the share. see reputation upside that Medical in meaningful strategic to What's the the in of engaging chain revenue differentiated researchers. biological the that and to will reach several scope in
week, support million project X $XX of signed XXXX. transformative One to today the vaccination we understanding in Congo news This approximately potential piece fiscal about for to in-country memorandum to of a has our with Democratic exciting like of project is year these opportunities. I'd Republic of generate Last efforts. a share the
it we B delivered million this put perspective outlook our to into expect year in top $XXX Medical. me Let how for for be on impacts 'XX, 'XX growth the order the we year. of On a
Our guidance for ever of the year which pipeline, is comes than our view richer been. from it's the
a deal, described. the confidence just we business. gives the not DRC outlook already DRC, of with the of For the pipeline program in from Medical's additional us but it included the the B And for magnitude upsizing
we've be was quarter the seen year. but pipeline, historically, revenue a a have We where and different the than in delivered the will with healthy cadence past, QX 'XX of largest growing in
our it provide a in When lumpy. the QX year versus remarks. prior growth business year, inside which We be a delivering down the QX different. to full but is is outlook his will is in currently we've meaningfully in Herman Medical on for but prepared agnostic no orders to hand, we've guided we mind, expect on and forecast still the anchored more Keep basis. color B have quarter, macro the environment,
it's B supported a say solutions strategic expanded processing scope in note and will retrieval because first traditional opportunity include began to that more also to the and project It's of DRC about bit that this But little Medical. biological a cold-chain me part initiative Azenta, that Let country X critical samples. significance. from important of this its form as the of vaccine
the and for prospects B role why enthusiastic project the about initiative of has of We're part this our human meaningful for still Azenta it's secondary the to tenets being the this key enabling Medical. this health in mission. X formed, Although engagement is important and come
to XXXX ramp overarching for vision XXXX, up fiscal like I'd and strategy we Azenta. our revisit into move and As
cold-chain services, to tools progression with products decade, as stand about biosample from of answer, as enabling later added I life then therapies. As markets sample company, customers the over truly business a started unique accelerate as expertise the refer emerging end-to-end to management a that platform sciences Multi-Omics or to breakthroughs we company here We today solutions. our the provides we sample and a it, in think recently, now most genomics past and management
end-to-end biosample on foremost, we're First leadership our to the management positions drive vector capabilities leverage the keen focused strengthening our key serve. growth. markets of we to But in next also we're and
and early, from discoveries like a still starting until multiomics of many samples measurements. example. Republic At it's the storage of into participants of certain format to keep our We biological to and automated the source them live first entities safe, systems in supply as who large focus samples Democratic Congo them able I'd to they're deal insight provide plans, for on on phenotype, with we're some While repositories to and cold any then interrogated cures. these analysis, workflow in for data be Azenta,
sample a Our ability chain entire and storage unique for critical customers. increasingly this to capability and is our workflow valuable sourcing, manage measurement
we samples tremendous the and these but of contributors And handle difficult are consent. samples of most interest that transport scarce they're of from there's descent, Today, samples in to biological are valuable, because obtain, European participants non-European are although descent.
We to valuable to means rare a have samples in permit hard-to-collect source not the our interest, and have of these only us samples, those infrastructure. platform simultaneously will to these in-country samples regions that secure research allow and on them allow through will access also
still our high-value but we've care on biological around only this and upside, expertise cold-chain our which management has to data has driven scientific $XXX clear: platform source multitude deliver manage and say, interrogate developed world-class to was samples a of and interested That's for others, of measure provide partners. of our to Hence, power discovery and teams not of tremendous portfolio use samples unique exercise to growth utilize to data accurate and the intend to million world. samples samples, these we the already to platform business a
The untapped is platform of value twofold. opportunity this
we over samples First, more accumulated to decades. of opportunity customer penetrate a that barely global into samples tap by we vast market collections as have order that bringing
them. do, us better get for we to giving at what are more we As customers do
measurement source leverage for in incented in can non-European that for annotated to meaning research multiomics use platform analysis. we be and stored of -- rare, are analysis, through future high-value and discovery, our the after Second, samples or even highly research follow-up use
future we'll to next the in leads steps The strategy in near capital where and us a clarity disciplined deployment been about what's conclusion of our the a strategy. focus
outstanding share of year our the program we've fiscal started today, we when profitability deploy This sheet, growth approved Board accelerate year, in which XX% of to years. Today, will our will to last As repurchased by of November. we plan approximately over opportunities in and XXXX. roughly Directors last million take we on repurchase will million to $XXX under in shares with commit still coming an $XXX that relative of authorization prudently which place the leave balance the us the cash enhance additional
cash, upgrade available acquisitions Our implementation, to that offerings and as prudent be provide ramping be to hundred investments sample likely revenue will plans strategic well years, adequate recurring operations, of in the we deployment growth enhance business. of run support cash should it's of tens dollars for have system range current and footprint of believe includes of our meet for of couple a customer of the for the million as to our couple portfolio structural data. tuck-in the road to in of map. durable dollars millions rationalization of And which remaining like demand, This to needs in next the organic the streamline support investments
To our be the we an would the capability, portfolio. service, beyond will acquisitions eye remain and that sample sample active not of valuable, our this creator unique to proposition we're as current companies But we growth of financially target and largest capability on do value enhance smaller, though and measurement accelerate strategically this management with the of will player management front, the providing the and unique our that necessarily attractive M&A cash require complete clear, compelling toward and are needs. also type add
it forecasted term, markets driven shareholder environment fundamental in our path drive a up potential. more the provider provide even will high-value to life will and expansion significant profitability over say, will to We're low-single-digits underpinnings While healthy short we're with or in long-term high-growth grow top a operational sciences mid- prepared for a be the we're to of his be and suffice revenue value. year challenging market XXXX be year. growth declining we of a serve during remarks. industry. increased in that's on line preeminent high-single-digits expect We to expansion. improvements Herman data confident macro that the next high-quality detail samples and slightly But to to by
we're At 'XX time, to fiscal in global We're I see to we're XXXX. ready markets by the outgrow our margin tireless laser-focused I to and into and improvement accomplishments want fiscal to we well on over head the team serve, and to expect and the market to we have am enhancement I as both entire the same and reiterate want incredibly operating more lines. year. the positioned in the XXXX we for profitability their convert from encouraged on customers the past contributions Azenta offerings. we our gross 'XX thank efforts how momentum value as
I today. comment want governance a turn brief I changes also Before over it Herman, announced to we to about make the
possess [ company's to nominations ongoing Hirsch to of Didier As Madaus you join we're Annual have know, Stockholders. both our strong and the to add end, And value. to them that the working of year. thrilled have support XXXX Board of the experience Martin look sciences and fresh directors in I the at new ], transformation Board perspectives, Didier announce We're continues to leadership Meeting their records strategy. closely and the to and excited forward life stockholder creating track with to Martin
Cueto. over Herman from Senior Herman segments, Herman. and has team. turn where as overseeing to make on the have new fortunate to operations. of the to Herman At on the contributions most President introduce and great XXth BD, call he's And recently served he him the hit regions, October, joined joins our to already this to CFO, I'll FP&A We're Since ground pleased I'm Finance, now board. you us time, us of running, Vice begun to
